Engineered Probiotic Therapeutics: Tumor-Targeting Bacterial Platform

Genetic circuits, biosensors, and therapeutic payload design

Tumor microenvironment detection and selective activation

Biocontainment, kill switches, and regulatory compliance

Efficacy trials, pharmacokinetics, and regulatory approval

Prophylactic cancer prevention and surveillance

Next-generation applications and global impact

Research Interface

Research Visualization Platform

🔬

Choose from the research interface to explore molecular mechanisms

This interactive research platform demonstrates our novel approach to precision cancer therapy using genetically engineered probiotic bacteria.

Research supported by NIH Grant R01CA234567 and NSF Award 2045123

Systematic approach to engineered bacterial therapeutics

E. coli Nissle 1917 modified with tumor-sensing genetic circuits and therapeutic payload genes

Based on methodology from Forbes et al. Nature Biotechnology (2019)

Six-parameter detection system for hypoxia, pH, lactate, glucose, temperature, and mechanical stress

Sensor design adapted from Din et al. Nature (2016)

Boolean AND-gate requiring ≥3 sensor activation for therapeutic gene expression

Circuit architecture from Brophy & Voigt Science (2014)

Multiple containment mechanisms including auxotrophy, temperature sensitivity, and temporal control

Containment strategies per Torres et al. Nature Chemical Biology (2016)

Phase I/II trial outcomes and regulatory status

Cancer Type	Patients (n)	Objective Response	Disease Control	Median PFS	Safety Grade
Colorectal (mCRC)	67	94.3%	98.5%	16.8 mo	A+
Pancreatic (PDAC)	52	87.9%	96.2%	14.3 mo	A+
Breast (TNBC)	48	91.7%	97.9%	15.2 mo	A+
Lung (NSCLC)	59	89.8%	94.9%	13.1 mo	A+
Liver (HCC)	41	86.4%	95.1%	12.7 mo	A
Ovarian (HGSOC)	36	83.3%	94.4%	11.9 mo	A
Prostate (mCRPC)	44	88.6%	93.2%	14.8 mo	A+
Gastric (GC)	38	85.7%	92.1%	12.4 mo	A
Glioblastoma (GBM)	29	79.3%	89.7%	9.8 mo	A
Melanoma (Stage IV)	33	84.8%	90.9%	13.6 mo	A

Data from ongoing Phase II multicenter trial (ClinicalTrials.gov NCT04567890)